Findings

What do systematic reviews say?

5 questions · 5 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 20%GRADE not reported 0 · 0%Very low 1 · 20%Low 2 · 40%Moderate 1 · 20%High 0 · 0%

Oral 5‐aminosalicylic acid vs placebo

Adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in adverse events compared with placebo (moderate certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.93 [0.73, 1.18]
5 studies · 1132 participants
Moderate

Oral 5‐aminosalicylic acid vs sulfasalazine

Serious adverse events · Patients with quiescent ulcerative colitis

The review found no eligible studies for this question.

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Serious adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with comparator 5‐aminosalicylic acid formulation (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.56 [0.14, 2.22]
1 study · 95 participants
Low

Oral 5‐aminosalicylic acid vs placebo

Serious adverse events · Patients with quiescent ulcerative colitis

Oral 5‐aminosalicylic acid showed no clear difference in serious adverse events compared with placebo (low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 0.6 [0.19, 1.84]
3 studies · 826 participants
Low

Oral 5‐aminosalicylic acid vs 5‐aminosalicylic acid (5‐ASA) (mesalazine)

Withdrawals due to adverse events · Patients with quiescent ulcerative colitis

It is very uncertain whether oral 5‐aminosalicylic acid changes withdrawal due to adverse events compared with comparator 5‐aminosalicylic acid formulation (very low certainty).

1 finding from 1 review

Oral 5‐aminosalicylic acid for maintenance of remission in ulcerative colitis 2020 · Cochrane Headline outcomes only
RR 1.25
5 studies · 457 participants
Very low